MiNK Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 14, 2023. MiNK is a clinical-stage biopharmaceutical company developing allogeneic iNKT cell therapies. It reported no product revenue; margins are therefore not meaningful.
Financial results and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Research and development expense | $3.43 million | $6.15 million | $12.18 million | $17.30 million |
| General and administrative expense | $1.80 million | $1.84 million | $5.24 million | $5.76 million |
| Operating loss | $5.22 million | $7.99 million | $17.42 million | $23.06 million |
| Net loss | $5.12 million | $6.33 million | $17.00 million | $20.22 million |
| Basic and diluted loss per share | $0.15 | $0.19 | $0.50 | $0.60 |
| Operating cash used | Not separately stated for quarter | Not separately stated for quarter | $12.73 million | $14.44 million |
- Cash and cash equivalents were $6.40 million at September 30, 2023, down from $19.64 million at December 31, 2022. Cash declined $13.24 million over the first nine months.
- Total assets were $7.46 million; current liabilities were $10.39 million. Stockholders’ deficit was $13.58 million, compared with a $0.40 million deficit at year-end 2022.
- MiNK reported $10.58 million due to related parties, principally Agenus. Agenus agreed not to require repayment of the related-party balance before December 31, 2024. The filing does not present conventional debt as a separate balance-sheet line.
- Interest income was $0.42 million for the first nine months. No material revenue or profitability was reported.
Changes versus comparable periods
- Q3 R&D expense fell 44%; nine-month R&D expense fell 30%, primarily due to clinical-trial timing and lower allocated Agenus service costs, partly offset by higher personnel costs.
- Nine-month G&A expense declined 9%, mainly from lower professional fees and Agenus service costs, partly offset by personnel and stock-based compensation costs.
- Net losses narrowed year over year, but the comparison is affected by 2022 other income: the prior-year periods included a gain related to reducing the Walloon Region advance liability ($1.56 million in Q3 and $2.72 million for nine months). 2023 other income was negligible.
Outlook, programs, and risks
- Management expects continuing operating losses and negative cash flows. It states that cash plus planned funding from Agenus or a third party is expected to meet liquidity needs for more than one year from issuance, but also discloses substantial doubt about going concern because that additional funding is uncertain. Management says it will adjust spending to preserve liquidity.
- Potential financing includes partnerships or out-licensing, grants and other non-dilutive funding, equity or debt financing, and—if other sources are unavailable—potential loans from Agenus. No committed financing amount or formal financial guidance is provided.
- Management described agenT-797 as its priority program. It reported Phase 1 solid-tumor findings presented at SITC in November 2023, including median progression-free survival exceeding six months, durable disease stabilization in approximately 30% of patients, and one ongoing partial response in gastric cancer at 10 months. These are early clinical findings, not established efficacy.
- The company plans a randomized Phase 1/2 expansion study of agenT-797 in relapsed/refractory gastric cancer with standard-of-care chemotherapy and immunotherapy, with or without Agenus’ botensilimab. It is also pursuing viral ARDS collaborations and non-dilutive funding; discussions were underway. IND-enabling work for engineered programs MiNK-215 and MiNK-413 continued, with an IND submission for MiNK-215 expected in 2024.
- A $2.2 million Walloon Region advance remains recorded as a current liability after the region obtained a default judgment seeking repayment. The company disclosed no material legal proceedings, but litigation outcomes are inherently uncertain.
- Other key risks include the early stage and cost uncertainty of clinical development, dependence on external financing and Agenus-related services, and the uncertain timing of regulatory approvals, partnerships, and potential cash inflows.
Important facts for investors to verify
- Whether Agenus or another source will provide additional funding, and the timing and terms of any such funding.
- Cash runway and operating cash burn in subsequent filings, given the $6.40 million quarter-end cash balance and going-concern disclosure.
- Progress, enrollment, safety, and durability of results in agenT-797 trials, including the planned gastric-cancer expansion.
- Status and potential financial effect of the Walloon Region judgment and the $2.2 million recorded liability.
- Terms and outstanding balance of Agenus-related obligations, and whether planned engineered-program IND milestones are achieved.